Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group

L. Smolej, Y. Brychtová, E. Cmunt, M. Doubek, M. Špaček, D. Belada, M. Šimkovič, L. Stejskal, I. Zygulová, R. Urbanová, M. Brejcha, J. Zuchnická, H. Móciková, T. Kozák, Czech CLL Study Group

. 2021 ; 193 (4) : 769-778. [pub] 20210222

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025768

Therapeutic options used to be very limited for treatment-naïve elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) before the introduction of chemo-immunotherapy. Because dose-reduced fludarabine-based regimens yielded promising results, the Czech CLL Study Group initiated a prospective observational study to assess safety and efficacy of low-dose fludarabine and cyclophosphamide combined with rituximab (FCR) in elderly/comorbid patients. Between March 2009 and July 2012, we enrolled 107 patients considered ineligible for full-dose FCR (median age, 70 years; median Cumulative Illness Rating Scale score, 5; median creatinine clearance, 69 ml/min). Notably, 77% patients had unfavourable biological prognosis [unmutated immunoglobulin heavy-chain variable-region gene (IGHV), 74%; deletion 17p, 9%). Fludarabine was reduced to 12 mg/m2 intravenously (iv) or 20 mg/m2 orally on days 1-3 and cyclophosphamide to 150 mg/m2 iv/orally on days 1-3. Grade 3-4 neutropenia occurred in 56% of the patients, but there were serious infections in only 15%. The median progression-free survival was 29 months, but was markedly longer in patients with mutated IGHV (median 53 months), especially in absence of del 11q or 17p (median 74 months). Low-dose FCR is a well-tolerated and effective first-line regimen for selected elderly/comorbid patients with CLL/SLL with favourable biology. The study was registered at clinicaltrials.gov (NCT02156726).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025768
003      
CZ-PrNML
005      
20250114091429.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.17373 $2 doi
035    __
$a (PubMed)33618437
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Smolej, Lukáš $u 4th Department of Internal Medicine - Haematology, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
245    10
$a Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group / $c L. Smolej, Y. Brychtová, E. Cmunt, M. Doubek, M. Špaček, D. Belada, M. Šimkovič, L. Stejskal, I. Zygulová, R. Urbanová, M. Brejcha, J. Zuchnická, H. Móciková, T. Kozák, Czech CLL Study Group
520    9_
$a Therapeutic options used to be very limited for treatment-naïve elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) before the introduction of chemo-immunotherapy. Because dose-reduced fludarabine-based regimens yielded promising results, the Czech CLL Study Group initiated a prospective observational study to assess safety and efficacy of low-dose fludarabine and cyclophosphamide combined with rituximab (FCR) in elderly/comorbid patients. Between March 2009 and July 2012, we enrolled 107 patients considered ineligible for full-dose FCR (median age, 70 years; median Cumulative Illness Rating Scale score, 5; median creatinine clearance, 69 ml/min). Notably, 77% patients had unfavourable biological prognosis [unmutated immunoglobulin heavy-chain variable-region gene (IGHV), 74%; deletion 17p, 9%). Fludarabine was reduced to 12 mg/m2 intravenously (iv) or 20 mg/m2 orally on days 1-3 and cyclophosphamide to 150 mg/m2 iv/orally on days 1-3. Grade 3-4 neutropenia occurred in 56% of the patients, but there were serious infections in only 15%. The median progression-free survival was 29 months, but was markedly longer in patients with mutated IGHV (median 53 months), especially in absence of del 11q or 17p (median 74 months). Low-dose FCR is a well-tolerated and effective first-line regimen for selected elderly/comorbid patients with CLL/SLL with favourable biology. The study was registered at clinicaltrials.gov (NCT02156726).
650    _2
$a senioři $7 D000368
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
650    _2
$a cyklofosfamid $x aplikace a dávkování $x škodlivé účinky $7 D003520
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x farmakoterapie $x mortalita $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a rituximab $x aplikace a dávkování $x škodlivé účinky $7 D000069283
650    _2
$a míra přežití $7 D015996
650    _2
$a vidarabin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D014740
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Brychtová, Yvona $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Cmunt, Eduard $u First Department of Medicine - Haematology, General University Hospital, Prague, Czech Republic
700    1_
$a Doubek, Michael $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Špaček, Martin $u First Department of Medicine - Haematology, General University Hospital, Prague, Czech Republic
700    1_
$a Belada, David $u 4th Department of Internal Medicine - Haematology, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
700    1_
$a Šimkovič, Martin $u 4th Department of Internal Medicine - Haematology, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic
700    1_
$a Stejskal, Lukáš $u Haematology/Tranfusiology Department, Silesian Hospital Opava, Opava, Czech Republic
700    1_
$a Zygulová, Irena $u Haematology/Tranfusiology Department, Silesian Hospital Opava, Opava, Czech Republic
700    1_
$a Urbanová, Renata $u Department of Haematology - Oncology, University Hospital, Olomouc, Czech Republic
700    1_
$a Brejcha, Martin $u Hospital Agel, Nový Jičín, Czech Republic $7 xx0105595
700    1_
$a Zuchnická, Jana $u Department of Haematology, University Hospital, Ostrava, Czech Republic
700    1_
$a Móciková, Heidi $u Department of Haematology, University Hospital Královské Vinohrady, Prague, Czech Republic
700    1_
$a Kozák, Tomáš $u Department of Haematology, University Hospital Královské Vinohrady, Prague, Czech Republic
710    2_
$a Czech CLL Study Group
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 193, č. 4 (2021), s. 769-778
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33618437 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20250114091425 $b ABA008
999    __
$a ok $b bmc $g 1714691 $s 1146275
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 193 $c 4 $d 769-778 $e 20210222 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20211013
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace